Literature DB >> 32981603

EGFR Exon 20 Insertion (A763_Y764insFQEA) Mutant NSCLC Is Not Identified by Roche Cobas Version 2 Tissue Testing but Has Durable Intracranial and Extracranial Response to Osimertinib.

Niamh Coleman1, David Woolf2, Liam Welsh3, Fiona McDonald4, Suzanne MacMahon5, Nadia Yousaf4, Sanjay Popat6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32981603     DOI： 10.1016/j.jtho.2020.05.006

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  4 in total

Review 1.  EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment.

Authors:  Alex Friedlaender; Vivek Subbiah; Alessandro Russo; Giuseppe Luigi Banna; Umberto Malapelle; Christian Rolfo; Alfredo Addeo
Journal:  Nat Rev Clin Oncol       Date:  2021-09-24       Impact factor: 66.675

Review 2.  Therapeutic advances in non-small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy.

Authors:  Yuan Cheng; Tao Zhang; Qing Xu
Journal:  MedComm (2020)       Date:  2021-12-14

3.  Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M.

Authors:  Yurong Wang; Ruipan Zheng; Peizhu Hu; Ziheng Zhang; Shujing Shen; Xingya Li
Journal:  BMC Cancer       Date:  2021-11-13       Impact factor: 4.430

4.  Comparison of sampling methods for next generation sequencing for patients with lung cancer.

Authors:  Kei Kunimasa; Shingo Matsumoto; Kazumi Nishino; Keiichiro Honma; Noboru Maeda; Hanako Kuhara; Motohiro Tamiya; Takako Inoue; Takahisa Kawamura; Toru Kimura; Tomohiro Maniwa; Jiro Okami; Koichi Goto; Toru Kumagai
Journal:  Cancer Med       Date:  2022-03-10       Impact factor: 4.711
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.